RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+11.17%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.93B
AUM Growth
+$3.93B
(-2.9%)
Cap. Flow
-$151M
Cap. Flow
% of AUM
-3.83%
Top 10 Holdings %
Top 10 Hldgs %
32.87%
Holding
120
New
16
Increased
40
Reduced
11
Closed
6
Top Buys
| 1 |
Surgery Partners
SGRY
|
$29.4M |
| 2 |
Eli Lilly
LLY
|
$26.3M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$23.4M |
| 4 |
Viking Therapeutics
VKTX
|
$21.4M |
| 5 |
Oscar Health
OSCR
|
$20.4M |
Top Sells
Sector Composition
| 1 | Healthcare | 96.88% |
| 2 | Consumer Staples | 1.95% |
| 3 | Industrials | 0.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Xenon Pharmaceuticals
XENE
$2.98B
| $54.1M | 1.37% |
1,255,577
| – | – |
|
27
Agilon Health
AGL
$530M
| $53.9M | 1.37% |
8,835,000
+205,000
| +2% | +$1.25M |
|
28
Merus
MRUS
$4.98B
| $51.6M | 1.31% |
1,146,560
+274,491
| +31% | +$12.4M |
|
29
Agios Pharmaceuticals
AGIO
$2.19B
| $51.6M | 1.31% |
1,764,505
-387,668
| -18% | -$11.3M |
|
30
Humana
HUM
$36.5B
| $51.1M | 1.3% |
147,408
-162,592
| -52% | -$56.4M |
|
31
Mirum Pharmaceuticals
MIRM
$3.71B
| $46.6M | 1.18% |
1,856,564
+5,100
| +0.3% | +$128K |
|
32
iRhythm Technologies
IRTC
$5.46B
| $45.5M | 1.16% |
392,250
+41,500
| +12% | +$4.81M |
|
|
SWAV
33
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $44M | 1.12% |
135,000
+15,000
| +13% | +$4.88M |
|
34
Ascendis Pharma
ASND
$11.8B
| $43.8M | 1.11% |
290,000
| – | – |
|
35
Sarepta Therapeutics
SRPT
$1.78B
| $42.4M | 1.08% |
327,600
| – | – |
|
36
Azenta
AZTA
$1.4B
| $41.9M | 1.06% |
694,750
+187,250
| +37% | +$11.3M |
|
|
OLK
37
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $39.4M | 1% |
1,676,500
| – | – |
|
38
Immunovant
IMVT
$2.56B
| $37.2M | 0.94% |
1,150,123
+166,822
| +17% | +$5.39M |
|
|
ACCD
39
DELISTED
Accolade, Inc. Common Stock
ACCD
| $37.1M | 0.94% |
3,540,000
+55,000
| +2% | +$576K |
|
40
Alnylam Pharmaceuticals
ALNY
$58.5B
| $36.5M | 0.93% |
244,000
+9,000
| +4% | +$1.35M |
|
41
Akero Therapeutics
AKRO
$3.74B
| $32.8M | 0.83% |
1,299,888
+218,824
| +20% | +$5.53M |
|
|
42
Oscar Health
OSCR
$4.31B
| $31.4M | 0.8% |
2,110,000
+1,375,000
| +187% | +$20.4M |
|
43
Pacira BioSciences
PCRX
$1.2B
| $30.8M | 0.78% |
1,055,500
| – | – |
|
44
Revolution Medicines
RVMD
$7.1B
| $29.8M | 0.76% |
923,681
+198,529
| +27% | +$6.4M |
|
45
Lifestance Health
LFST
$2.13B
| $29.5M | 0.75% |
4,780,000
+245,000
| +5% | +$1.51M |
|
|
46
Surgery Partners
SGRY
$2.91B
| $29.4M | 0.75% |
+985,000
| New | +$29.4M |
|
47
Warby Parker
WRBY
$3.2B
| $28.3M | 0.72% |
2,080,000
+51,700
| +3% | +$704K |
|
|
INZY
48
DELISTED
Inozyme Pharma
INZY
| $28.2M | 0.72% |
3,681,174
| – | – |
|
49
Inspire Medical Systems
INSP
$2.77B
| $28M | 0.71% |
130,500
+31,500
| +32% | +$6.77M |
|
50
Legend Biotech
LEGN
$6.41B
| $28M | 0.71% |
499,486
+7,042
| +1% | +$395K |
|